Hypoparathyroidism Epidemiology Forecast 2026-2035

Read more about this report - Request a Free Sample

Hypoparathyroidism Epidemiology Forecast Report Coverage

Expert Market Research's “Hypoparathyroidism Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of hypoparathyroidism. It projects the future incidence and prevalence rates of hypoparathyroidism cases across various populations. The study covers age, gender, and type as major determinants of the hypoparathyroidism population. The report highlights patterns in the prevalence of hypoparathyroidism over time and projects future trends based on multiple variables.

Hypoparathyroidism Understanding: Disease Overview

Hypoparathyroidism is an endocrine disorder characterized by insufficient secretion of parathyroid hormone (PTH), resulting in hypocalcemia and hyperphosphatemia. It commonly occurs due to surgical removal of the parathyroid glands, autoimmune conditions, or genetic mutations. Clinical symptoms include muscle cramps, tingling sensations, and neuromuscular irritability. Hypoparathyroidism epidemiology indicates that it is a rare but increasingly recognized condition due to improved diagnostic testing. Chronic cases can lead to complications affecting bone health, kidney function, and neurological stability, making early detection essential for disease management.

Hypoparathyroidism Epidemiology Perspective

The hypoparathyroidism epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the hypoparathyroidism epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for hypoparathyroidism and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• As per Sigridur Bjornsdottir et al., 2022, the hypoparathyroidism prevalence ranges from 6.4 to 37 per 100,000 population across countries, and the incidence is reported at 0.8 to 2.3 per 100,000 per year, with thyroidectomy or head and neck surgery complications contributing to approximately 75% of cases.
• According to Maulik Maheshwari et al., 2024, one study reported a permanent hypoparathyroidism incidence of approximately 10.7% one year post-surgery, while another cohort study found a prevalence of 10.3%, with higher rates in females at 12.1% compared to males at 3.2%.
• According to Elena Tsourdi et al., 2025, the annual incidence of hypoparathyroidism is estimated at 2.6 per 100,000 in India, with regional differences existing in epidemiology, etiology, and diagnostic and therapeutic strategies, reflecting varying surgical rates and healthcare infrastructure across nations.
• According to Takeda Pharmaceuticals, hypoparathyroidism predominantly affects females, approximately 75%, with a mean age of 51.6 years, and is frequently associated with comorbid conditions such as postsurgical hypothyroidism and thyroid malignancies.

Read more about this report - Request a Free Sample

Country-wise Hypoparathyroidism Epidemiology

The hypoparathyroidism epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of hypoparathyroidism differs between countries owing to factors such as genetic diversity across populations, the prevalence of thyroid and parathyroid surgeries, and variations in healthcare infrastructure and diagnostic capabilities. Countries with rare disease registries and robust research programs tend to have more accurate case reporting. According to Syeda Rabiah Shahid et al., 2026, hypoparathyroidism affects approximately 70,000–90,000 individuals in the United States, confirming its classification as a rare but clinically significant endocrine disorder.

Hypoparathyroidism: Treatment Overview

Treatment of hypoparathyroidism aims to maintain normal calcium and phosphate balance while preventing complications. Standard therapy includes oral calcium supplements and active vitamin D analogs to restore serum calcium levels. In refractory cases, recombinant parathyroid hormone therapy may be used for long-term control. Management of endocrine disorders also involves regular monitoring of calcium, phosphate, and renal function to avoid complications such as kidney stones or calcification. Personalized treatment strategies are essential to ensure stable metabolic control and improve patient quality of life over time.

Key Questions Answered

• What are the key findings of hypoparathyroidism epidemiology in the 8 major markets?
• What will be the total number of patients with hypoparathyroidism across the 8 major markets during the forecast period?
• What was the country-wise hypoparathyroidism epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of hypoparathyroidism patients during the forecast period of 2026-2035?
• Which key factors would influence the shift in the patient population of hypoparathyroidism during the forecast period of 2026-2035?
• What are the currently available treatments for hypoparathyroidism?
• What are the disease risks, signs, symptoms, and unmet needs of hypoparathyroidism?

Scope of the Hypoparathyroidism Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of hypoparathyroidism based on several factors.
• Hypoparathyroidism Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The hypoparathyroidism report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

Anaplastic Thyroid Cancer Drugs Market

Hypothyroidism Market